Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>DCGI has approved market authorisation for the COVID-19 vaccine <keyword id="10678894" type="General" weightage="100" keywordseo="covovax" source="Orion">Covovax</keyword> as a heterologous booster dose for adults.</li><li>The DCGI's approval came following recommendations by the <keyword id="3923779" type="General" weightage="50" keywordseo="subject-expert-committee" source="Orion">Subject Expert Committee</keyword> of the Central Drugs Standard Control Organisation (<keyword id="6375144" type="General" weightage="50" keywordseo="cdsco" source="Orion">CDSCO</keyword>).</li></ul>The <keyword id="6386816" type="General" weightage="50" keywordseo="drug-controller-general-of-india" source="Orion">Drug Controller General of India</keyword> (DCGI ) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of <keyword id="9617748" type="General" weightage="50" keywordseo="covishield" source="Orion">Covishield</keyword> or <keyword id="9485939" type="General" weightage="50" keywordseo="covaxin" source="Orion">Covaxin</keyword>, official sources said on Monday. The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Prakash Kumar Singh, Director of Government and Regulatory Affairs at the <keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword> (<keyword id="52604" type="General" weightage="80" keywordseo="sii" source="Orion">SII</keyword>), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating COVID-19 pandemic situation in some countries, an official source had said. "The Subject Expert Committee of the CDSCO on Wednesday deliberated on the issue and had recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said. The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in children aged 7- 11 years on June 28 last year subject to certain conditions. Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted emergency-use listing by the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword> (WHO) on December 17, 2021. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in <keyword id="3658" type="General" weightage="50" keywordseo="india" source="Orion">India</keyword> and low-and-middle-income countries. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/amazon-great-republic-day-sale-2023-best-deals-and-offers-on-tvs/articleshow/96987966.cms">Amazon Great Republic Day Sale 2023 – Best deals and offers on TVs</a> <a href="https://www.businessinsider.in/tech/apps/news/these-audio-setting-tweaks-can-make-music-sound-better-on-spotify/articleshow/96876010.cms">These audio setting tweaks can make music sound better on Spotify</a>

Serum Institute's Covovax gets DCGI approval as a heterologous booster dose

New Delhi, As India gets readied for a <keyword id="10424473" type="UNKNOWN" weightage="20" keywordseo="massive-covid-vaccination-programme">massive Covid vaccination programme</keyword>, heath experts on Sunday said that 21 days is an ideal gap between the first and the <keyword id="10424474" type="UNKNOWN" weightage="20" keywordseo="second-booster-dose">second booster dose</keyword>, and those who get vaccinated have to maintain the same health hygiene as they are supposed to do sans vaccine for a certain time period. Union Health Ministry Secretary Rajesh Bhushan had said that 30 crore people have been listed in prioritised population groups, which involves one crore healthcare workers, two crore personnel from the police department, armed forces, home guard, civil defence organisation and 27 crore people above the age of 50 and below 50 with co-morbidities. The government is expected to roll out its <keyword id="9849917" type="UNKNOWN" weightage="20" keywordseo="first-vaccines">first vaccines</keyword> in the next few weeks with at least three candidates under the <keyword id="6681091" type="UNKNOWN" weightage="20" keywordseo="active-consideration">active consideration</keyword> of India's drug regulator. According to Dr Manoj Goel, Director, Pulmonology at Fortis Hospital in Gurugram, after taking the first dose, the second dose has to be ideally taken on the 21st day. "After the vaccination, one can resume their normal day to day activities. In between also, there are no guidelines to sit at home and people can carry on their usual activities by taking the basic precautions like social distancing, wearing a mask and frequent sanitising of hands," Goel told IANS. The Union Health Ministry had said that 1.54 lakh vaccinators or auxiliary nurse midwives will administer the <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword> vaccine to people under the universal immunisation programme when the vaccination process begins. According to Dr Jyoti Mutta, Senior Consultant, Microbiology at Sri Balaji Action Medical Institute in New Delhi, there are a number of vaccines which have different schedules and these vaccine schedules are determined by clinical trials. "Talking about Pfizer vaccine in this regard, two doses are suggested 21 days apart and two doses 28 days apart for AstraZeneca vaccine. Also, the proper rest and precautions are suggested during this period in order to avoid infection and proper care," she told IANS. Dr Mutta also stressed that staying at home is not particularly defined as a precautionary measure but complete care is recommended. "Taking precautions like wearing a mask, social distancing and hand hygiene is important to avoid infection," she noted. Dr Neha Gupta, Infectious Diseases Physician at Medanta Hosptial in Gurugram told IANS: "Vaccine requires two doses 21 days apart and usually the protective efficacy is seven days after the second dose. So, patients need to continue precautions after the first dose of vaccine." There are as many as eight <keyword id="8983421" type="UNKNOWN" weightage="20" keywordseo="Covid-vaccine">Covid vaccine</keyword> candidates under different stages of clinical trials which could be ready for authorisation in near future. The vaccines include Covaxin, Astrazeneca and Oxford university developed and Serum Institute of India manufactured <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword>, ZyCoV-D by Zydus Cadila, Russian vaccine candidate Sputnik-V, NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabelled vaccines - Recombinant Protein antigen-based vaccine by Biological E Limited and Inactivated rabies vector platform by <keyword id="7330627" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech-Limited">Bharat Biotech Limited</keyword>. Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have already applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for their potential Covid-19 vaccines. SEE ALSO: <a href="https://www.businessinsider.in/science/space/news/dos-and-donts-during-solar-eclipse-surya-grahan/articleshow/76436997.cms">The do’s and don’ts of a Solar Eclipse — here what you need to know to protect yourself</a> <a href="https://www.businessinsider.in/science/space/news/solar-eclipse-december-2020-time-date-everything-you-need-to-know/articleshow/79697355.cms">The total solar eclipse and its 'diamond rings' won't be visible in India on December 14</a>

Experts believe COVID-19 vaccine doses need a at least a 21-day gap between them

As of now as many as 110 countries have recognized India's Covid vaccines -- <keyword id="9617748" type="General" weightage="20" keywordseo="Covishield" source="Orion">Covishield</keyword> and <keyword id="9485939" type="General" weightage="20" keywordseo="Covaxin" source="Orion">Covaxin</keyword> -- and have agreed to mutual recognition of Covid-19 vaccination certificates with India, said official sources in the Union Health Ministry. A source with the Ministry said that at present, 110 countries have agreed to mutual recognition of vaccination certificates and those who recognise Indian vaccination certificates of travellers fully vaccinated with Covishield or World Health Organisation(WHO)-approved Covid vaccines. As per the new travel guidelines issued by the Union Health Ministry, if a fully vaccinated traveller is coming from a country with which India has reciprocal arrangements for mutual acceptance of WHO-approved Covid-19 vaccines, they will be allowed to leave the airport and must self-monitor their health for 14 days' post arrival. If partially or not vaccinated travellers visit India, they will have to submit their sample for post-arrival Covid-19 test at the point of arrival after which they will be allowed to leave the airport. They will have to be undergo home quarantine for seven days and undertake re-test on the eighth day of arrival in India and if found negative, further self-monitor their health for next seven days. "Travellers artiving from countries excluding those at risk, will be allowed to leave the airport and must self-monitor their health for 14 days' post arrival. This is applicable to travellers from all countries, including with which reciprocal arrangements for mutual acceptance of WHO-approved Covid-19 vaccines also exist," said the new international arrival guidelines. Of eight WHO-approved vaccines against Covid-19 in emergency use listing, two vaccines -- Covaxin and Covishield -- are from India. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/indias-covaxin-77-8-effective-for-covid-19-says-lancet-report/articleshow/87661300.cms">India's Covaxin 77.8% effective for COVID-19, says Lancet Report</a> <a href="https://www.businessinsider.in/science/health/news/ideal-time-for-booster-dose-for-covid-19-vaccine-is-6-months-after-second-dose-says-bharat-biotech-md/articleshow/87629337.cms">Ideal time for COVID-19 booster shot is six months after the second dose, says Bharat Biotech MD</a>

Covishield and Covaxin are now recognized by 110 countries

<ul><li>The IPO of Tega Industries was subscribed 4.6 times on the first day of issue on December 1.</li><li>Tega is looking to raise ₹600 crore from this IPO, which is entirely an offer for sale of 1.3 crore equity shares.</li><li>Retail investors can bid for a minimum of 33 shares with an investment of ₹14,949 per share.</li></ul>The initial public offering (IPO) of Tega Industries, a manufacturer of consumables for the mining industry, was subscribed 4.6 times on the first day of issue on December 1. The public issue reported a strong demand from non-institutional buyers as well as retail investors, who oversubscribed the shares. The company received quite an underwhelming response from qualified institutional buyers (QIB) on day 1. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investor category </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscription (times) </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Qualified Institutions </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">0.07 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Non-Institutional Buyers </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">4.17 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Retail Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">7.51 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Total </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">4.67 </td></tr></tbody></table>Source: BSE Tega is looking to raise ₹600 crore from this public issue, which is entirely an offer for sale of 1.3 crore equity shares by promoters and existing shareholders. The company’s grey market premium (GMP) was at ₹370 apiece in the grey marker on December 1, representing a hike of ₹60 from a day ago. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stakeholders </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Offer for Sale </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Madan Mohan Mohanka </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">33.14 lakh equity shares </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Manish Mohanka </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">6.63 Lakh equity shares </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"> TA Associates </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">96.92 lakh equity shares </td></tr></tbody></table>The company’s shares are likely to list on the stock market on December 13, 2021. The price band for the public issue has been set at ₹443 to ₹453. Retail investors can bid for a minimum of 33 shares with an investment of ₹14,949 per share. Tega Industries provides customised solutions to the mining, bulk material handling and transportation industry like manufacturing of wear resistant lining components required for grinding, sizing and others. It has a product portfolio of more than 55 mineral processing and material handling products. The company has six manufacturing sites, including three in India — Dahej in Gujarat, Samali and Kalyani in West Bengal, and three sites in major mining hubs of Chile, South Africa and Australia. SEE ALSO <a href="https://www.businessinsider.in/india/news/international-flights-from-india-will-not-be-resuming-on-december-15-due-on-concerns-of-new-covid-19-variant/articleshow/88029203.cms" data-type="tilCustomLink">International flights from India will not be resuming on December 15 due to concerns of new COVID-19 variant</a> <a href="https://www.businessinsider.in/personal-finance/news/here-is-how-you-can-link-your-pan-before-applying-for-the-lic-ipo/articleshow/88032810.cms" data-type="tilCustomLink">Do you own an LIC policy? Here is how you can link your PAN before applying for the LIC IPO</a> <a href="https://www.businessinsider.in/india/news/serum-institute-seeks-drug-regulators-approval-to-start-booster-doses-of-covishield/articleshow/88034074.cms" data-type="tilCustomLink">Serum Institute seeks drug regulator's approval to start booster doses of Covishield</a>

You Searched For "covishield booster dose" and got 4 results

Serum Institute's Covovax gets DCGI approval as a heterologous booster dose

PTI

Experts believe COVID-19 vaccine doses need a at least a 21-day gap between them

IANS

Covishield and Covaxin are now recognized by 110 countries

IANS

Tega Industries’ IPO oversubscribed on Day 1 — GMP at ₹370

Kritti Bhalla

Popular Keywords

Buying Guides